Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02686762 · ClinicalTrials.gov registry record · Phase 2
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
A Phase 2 study of Liver Diseases and Non-alcoholic Steatohepatitis, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 318
- Enrollment target
- 20
- Study locations
NCT02686762 is a Phase 2 study of Liver Diseases and Non-alcoholic Steatohepatitis that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 318 participants, below the 61,149-participant average among 33 other Liver Diseases trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT02686762, a Phase 2 study of Liver Diseases and Non-alcoholic Steatohepatitis, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 318 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Emricasan (5 mg)
- DRUG Emricasan (50 mg)
Study Locations (20)
California
- Fresno Clinical Research Center - Freestone
- UCLA The Pfleger Liver Institute - Los Angeles
- Gastrointestinal Biosciences - Los Angeles
- Surinder Singh Saini, M.D., Inc. - Newport Beach
- California Liver Research Institute - Pasadena
- Inland Empire Liver Foundation - Rialto
- University of California Davis Medical Center - Sacramento
- University of California San Diego Medical Center - San Diego
- Cedars Sinai Medical Center - West Hollywood
Florida
- UF Hepatology Research at CTRB - Gainesville
- Florida Digestive Health Specialist - Lakewood Rch
- Miami Veterans Administration Healthcare System - Miami
- University of Miami/Schiff Center for Liver Diseases - Miami
- Florida Hospital Orlando Transplant Institute - Orlando
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
- Howard University - Washington D.C.
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- University of Arizona Clinical and Translational Sciences Research Center - Tucson
Arkansas
- Preferred Research Partners, Inc. - Little Rock
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2016-01-26 |
| Est. Completion | 2019-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02686762
The ClinicalTrials.gov registry entry for NCT02686762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61,149-participant average among 33 other Liver Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Liver Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02686762 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02686762 about?
NCT02686762 is a clinical study titled "Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis". This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg...
What is the current status of trial NCT02686762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 318 participants. The study started on 2016-01-26. Estimated completion is 2019-02-28.
What conditions does trial NCT02686762 study?
This clinical trial studies the following conditions: Liver Diseases, Non-alcoholic Steatohepatitis, Fibrosis.
What interventions are being tested in trial NCT02686762?
The interventions under investigation include: Placebo (DRUG), Emricasan (5 mg) (DRUG), Emricasan (50 mg) (DRUG).
Who is sponsoring clinical trial NCT02686762?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02686762 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RECRUITING
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Genetic Collection Protocol
RECRUITING
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.